key: cord-0984329-mkos3h35
authors: Razzaq, Misbah; Iglesias, Maria Jesus; Ibrahim-Kosta, Manal; Goumidi, Louisa; Soukarieh, Omar; Proust, Carole; Roux, Maguelonne; Suchon, Pierre; Boland, Anne; Daiain, Delphine; Olaso, Robert; Havervall, Sebastian; Thalin, Charlotte; Butler, Lynn; Deleuze, Jean-François; Odeberg, Jacob; Morange, Pierre-Emmanuel; Trégouët, David-Alexandre
title: An artificial neural network approach integrating plasma proteomics and genetic data identifies PLXNA4 as a new susceptibility locus for pulmonary embolism
date: 2021-07-07
journal: Sci Rep
DOI: 10.1038/s41598-021-93390-7
sha: 53924e6e573e7e29a2b7052beba1eb900910a2a4
doc_id: 984329
cord_uid: mkos3h35

Venous thromboembolism is the third common cardiovascular disease and is composed of two entities, deep vein thrombosis (DVT) and its potential fatal form, pulmonary embolism (PE). While PE is observed in ~ 40% of patients with documented DVT, there is limited biomarkers that can help identifying patients at high PE risk. To fill this need, we implemented a two hidden-layers artificial neural networks (ANN) on 376 antibodies and 19 biological traits measured in the plasma of 1388 DVT patients, with or without PE, of the MARTHA study. We used the LIME algorithm to obtain a linear approximate of the resulting ANN prediction model. As MARTHA patients were typed for genotyping DNA arrays, a genome wide association study (GWAS) was conducted on the LIME estimate. Detected single nucleotide polymorphisms (SNPs) were tested for association with PE risk in MARTHA. Main findings were replicated in the EOVT study composed of 143 PE patients and 196 DVT only patients. The derived ANN model for PE achieved an accuracy of 0.89 and 0.79 in our training and testing sets, respectively. A GWAS on the LIME approximate identified a strong statistical association peak (rs1424597: p = 5.3 × 10(–7)) at the PLXNA4 locus. Homozygote carriers for the rs1424597-A allele were then more frequently observed in PE than in DVT patients from the MARTHA (2% vs. 0.4%, p = 0.005) and the EOVT (3% vs. 0%, p = 0.013) studies. In a sample of 112 COVID-19 patients known to have endotheliopathy leading to acute lung injury and an increased risk of PE, decreased PLXNA4 levels were associated (p = 0.025) with worsened respiratory function. Using an original integrated proteomics and genetics strategy, we identified PLXNA4 as a new susceptibility gene for PE whose exact role now needs to be further elucidated.

Plasma labelling and protein profiling assay. Plasma samples were diluted 1:10 in filtered 1xPBS and labelled with biotin (NHS-PEG4-Biotin, Thermo Scientific) for 2 h at 4 °C. The labelling process was terminated by the addition of 12,5ul of 0.5 M HCl pH:8.0 to each sample for 20 min and consecutively storage at − 20 °C until usage 22 . Labelled plasma samples were diluted 1:50 in PVX casein buffer + 10% (v/v) rabbit IgG (0.1% casein, 0.5% polyvinyl alcohol, 0.8% polyvinylpyrrolidone, prepared in 1xPBS). Diluted samples were heat-induced to achieve epitope retrieval for 30 min at 56 °C. Five microliters of the SBA were mixed with 45ul of heat-treated samples for [16] [17] [18] h, at RT and constant shake. Unbound complexes were removed by 2 consecutive washes with PBS-T and antibody-bound complexes were cross-linked by resuspending the beads in 0.4% PFA-PBS for 10 min. R-phycoerythrin-conjugated streptavidin (1:750, PBS-T; Invitrogen) was added to all samples for 30 min www.nature.com/scientificreports/ followed by 2 times washes. Relative amount of each protein complex was expressed as median of fluorescence intensity (MFI) by read out on a FlexMAP3D.

This study is composed of 339 VTE patients with documented idiopathic isolated PE or DVT selected according to the same criteria as the MARTHA participants, with the exception that the age of VTE onset was below 50 yrs. Brief characteristics of the EOVT participants are shown in Supplementary Table 3 while detailed description can be found in 21,23 . Machine-learning framework for identifying a molecular predictor of PE risk.

Step 1: Normalization. First, all HPA variables and biological traits were normalized and scaled to have 0 mean and 1 variance to avoid major artificial influence of variables with large range of variations.

Step2: Edited nearest neighbors. As our aim was to identify new molecular markers associated with PE, we hypothesized that conducting our discovery phase on isolated PE, an expected less heterogeneous class of VTE patients than the class of patients with both DVT and PE, will increase our chance to identify novel relevant molecular players. As a consequence, we decided to build our ANN model only on patients with isolated PE (N = 95) or with DVT (N = 1105). However, due to the imbalance nature of this dataset with ~ 10 more samples in the DVT class than in the PE class, we applied the edited nearest neighbors (ENN) algorithm, an under sampling method usually used in the field of pattern recognition or classification in presence of unbalanced samples 17 . This method relies on under sampling unit of analysis, in our case individuals, from the majority class by removing the most heterogeneous units. It consists in computing the Euclidean distance between each pair of individuals from their proteomics and biological data and to remove samples whose clinical phenotype (here DVT) is not consistent with that of his/her k nearest neighbors (k = 3 in this work). This led us to the selection of the so called ANN dataset composed of N = 497 DVT and N = 95 PE patients for building our ANN model.

To build our ANN model, the ANN dataset was divided into a training set composed of 576 patients (487 DVT and 89 PE) and a testing set of 16 patients (10 DVT and 6 PE), the latter being used for testing the accuracy of the ANN model derived from the former. This allocation was chosen so that the number of PE cases used for training was sufficiently large. Because the application of a standard ANN methodology to our training set would lead to unstable network for predicting PE due to the imbalance nature of the input data with ~ 5 times more DVT than PE patients, an interactive ANN framework was adopted:

At each iteration i,

• A random sample of 30 PE patients and 100 DVT patients is selected from the training set and a sample of 70 synthetic PE samples are generated using the ADASYN algorithm 24 . ADASYN is an adaptive synthetic data generation method where new samples are generated based on the weighted distribution for minority class samples with two main advantages, resolving data imbalance and forcing classifiers to be more sensitive to the minority class. This strategy led to a balanced dataset Di of 100 PE and 100 DVT (synthetic) patients on which a ANN is built. • Using the Di dataset further splitted randomly into 90%/10% training/testing subsamples, a two hiddenlayers feed forward neural network was implemented (see Supplementary data for an illustration of the neural network's structure). In addition to the input layer corresponding to the number of proteomic and biological variables (n = 395), the proposed neural network included a first hidden layer with 395 neurons, a second layer with 128 neurons and an output layer with 2 neurons, representing the DVT and PE classes respectively. The number of neurons were selected by trial and error approach under the constraint that the number of neurons shall be smaller or equal to the number of input variables and higher than the number of output classes.

The Rectified Linear Unit (ReLU) function 25 was used to activate hidden layers while the softmax activation function 26 was used to generate class probabilities in the output layer.

After fixing the number of nodes, layer and activation function, the process of training the neural network can start. Starting from random weights, forward propagation is used to generate the output of all nodes at all layers while moving from the input to the output layers. The generated final output is compared to the observed class phenotype and an error is calculated using the cross-entropy function 27 . Iteratively, this error was then backpropagated using a gradient descent algorithm 28 (with learning of 0.01 and batch size of 32) to update weights according to their contribution to the error. In order to reduce over-fitting and obtain the best performing model, the callback feature proposed by the Keras open-source library (https:// keras. io/) was employed.

Step4: Local interpretable model-agnostic explanations (LIME). As a neural network is often considered a black box without telling much about which, and how, input variables contribute to the prediction, the LIME methodology 18 was applied to the final ANN model obtained at Step 3 in order to inform about which input variables (i.e. plasma protein levels) contribute to PE risk prediction and what are the relative weights using a linear approximation of the ANN model. Genome wide genotyping. As previously described 16 

Imputed SNPs with imputation quality r 2 greater than 0.5 and with minor allele frequency (MAF) greater than 0.01 were tested for association with the LIME predictor derived in 574 MARTHA participants. Associations with statistical p-value < 5 × 10 -8 were considered as genome-wide significant.

Genetic Association Analysis with PE risk. The candidate SNP identified from the GWAS on the LIME predictor was tested for its association with PE risk, both in MARTHA and EOVT participants. For this, we employed the Cochran-Armitage trend for association applied to the best guessed genotypes inferred from the imputed allele dosage at the SNP of interest. Logistic regression was also employed to estimate genetic effects adjusted for age and sex.

Annotation of the candidate SNP. Identified SNP was examined for association with the expression of its structural gene via publicly available genome-wide gene expression data from multiple cell lines and tissues incl. 29 Inclusion was based on a confirmed diagnosis of SARS-CoV2 infection based on reverse-transcriptase polymerase chain reaction (RT-PCR) viral RNA detection of nasopharyngeal or oropharyngeal swabs, or clinical presentation with COVID-19 disease. Exclusion criteria were age < 18 years. Patients were followed longitudinally from inclusion, and blood samples for biobanking of plasma samples were collected shortly after hospital admission and every 2-3 days during the hospital stay. Procedures for blood sampling and plasma preparation have been previously described 34 . Demographic data, routine lab results, comorbidity and information and variables reflecting clinical deterioration, including respiratory support were obtained from medical records. Patients were divided into groups based on respiratory support classified at the time of a sample was drawn, classified into a categorical variable 'Respiratory Index' or RI, defined as RI = 0 for no respiratory support, RI = 1 for ≤ 5 L of oxygen on nasal cannula or mask, RI = 2 for > 5 L of oxygen on nasal cannula or mask, RI = 3 for noninvasive respiratory support and RI = 4 for intubation. Level of respiratory support and oxygen supplementation were set at the discretion of the treating physician. For the current study, 339 samples collected from 112 patients were available, with at least 2 samples for 71 of the patients (63.4%). Baseline characteristics are shown in Supplementary Table 4 . The HPA antibody HPA052141 targeting the PLXNA4 protein was used to measure PLXNA4 levels in the 339 available samples from the COMMUNITY study, following a similar protein profiling protocol as that described above.

Association of PLXNA4 plasma levels with respiratory index at baseline was tested using linear regression models. To handle multiple time point measurements, association of PLXNA4 plasma levels with RI was further investigated using all available longitudinal measurements using a linear mixed effect model as implemented in the nlme R package. Analyses were adjusted for age, sex and body mass index.

Whole genome sequencing. From the whole MARTHA study, 200 patients had been selected for whole genome sequencing. These patients were selected to have experienced VTE in absence of strong environmental and genetic risk factors. Besides, these patients should have family history of VTE or multiple unprovoked VTE events, such clinical patterns being compatible with the existence of an underlying VTE causing genetic defect. Genomic DNA was extracted from peripheral blood, using the BioRobot EZ1 workstation. The DNA concentration was determined using the Qubit assay kit (Thermofisher). Whole genome sequencing was performed at the Centre National de Recherche en Génomique Humaine (CNRGH, Institut de Biologie François Jacob, Evry, France). After a complete quality control, 1 µg of genomic DNA was used for each sample to prepare a library for whole genome sequencing, using the Illumina TruSeq DNA PCR-Free Library Preparation Kit, according to the manufacturer's instructions. After normalization and quality control, qualified libraries were sequenced on a HiSeqX5 instrument from Illumina (Illumina Inc., CA, USA) using a paired-end 150 bp reads strategy. One lane of HiSeqX5 flow cell was used per sample specific library in order to reach an average sequencing depth of 30× for each sequenced individual. Sequence quality parameters have been assessed throughout the sequencing run and standard bioinformatics analysis of sequencing data was based on the Illumina pipeline to generate FASTQ file for each sample. FastQ sequences were aligned on human genome hg37 using the BWA-mem program 35 www.nature.com/scientificreports/ Variant calling was performed using the GATK HaplotypeCaller (GenomeAnalysisTK-v3.3-0, https:// softw are. broad insti tute. org/ gatk/ docum entat ion/ artic le. php? id= 4148). Single-sample gVCFs files were then aggregated using GATK CombineGVCFs and joint genotyping calling performed by GATK GenotypeGVCFs. Recalibration was then conducted on the whole gVCF following GATK guidelines. Following GATK VQSR, we retained single nucleotide variants in the 99.5% tranche sensitivity threshold and indels in the 99% tranche sensitivity threshold for further analysis and annotated them using Annovar 36 . As a strategy to identify candidate variants that could explain the VTE phenotype in individuals with discordant class prediction, we first prioritized variants that were likely functional (stop loss/stop gain, frameshift, non-synonymous and splicing variants), located in known VTE associated genes (ABO, ARID4A, C4BPB, EIF5A, F2, F3, F5, F8, F9, F13A1, FGG, GRK5, MPHOSPH9, MAST2, NUGCC, OSMR, PLAT, PLCG2, PLEK1, PROC, PROS1, SCARA5, SERPINC1, SLC44A2, STAB2, STX10, STXBP5, THBD, TSPAN15, VWF) [37] [38] [39] , that have not been reported or at a low frequency (< 1‰) in public genomic data repositories (dbSNP, GnomAD) and that was present in only one of the 200 sequenced patients. If no candidate variants was identified in known VTE genes, we extended our search to whole coding genes and also took into account the predicted deleteriousness of selected candidates using in silico tools such as SIFT, PolyPhen and CADD-v1.2 40 to further reduce the number of candidates.

Data description. The MARTHA proteomics substudy was composed of 1,388 VTE patients among which 1105 were diagnosed for DVT, 95 with isolated PE and 188 with both DVT and PE ( Table 1) .

Exploration of this dataset using high-dimensional visualization techniques including principal component analysis, t-distributed stochastic neighbor embedding (t-SNE) 41 and Uniform Manifold Approximation and Projection (UMAP) 42 did not reveal any specific stratification in the data nor outliers (Fig. 2 ) but rather illustrates that the three class of patients (DVT, PE, DVT + PE) could not be easily separated.

Artificial Neural Network for PE-As the accuracy/efficiency of any ANN strongly depend on the quality/ homogeneity of the input data, we first applied the edited nearest neighbors algorithm 17 to perform under sampling of the majority class (DVT) and obtain a more homogeneous set of DVT patients, and further discarded the DVT + PE class to avoid adding noise in discriminating between PE and non PE patients. This strategy led to the selection of a subsample (referred thereafter to as the ANN dataset) of 592 patients (497 DVT and 95 PE) www.nature.com/scientificreports/ whose proteomics/biological entered the ANN analysis. Visual inspection of the proteomics and biological data in the selected ANN sample is shown in Supplementary Fig. 2 .

A two hidden-layers ANN was then built from the ANN dataset with a training set of 576 patients (487 DVT and 89 PE) and a testing set of 16 patients (10 DVT and 6 PE). This allocation was chosen so that the number of PE cases used for training was sufficiently large. Because the training set presented with a strong imbalance with respect to the DVT/PE classes with ~ 5 times more DVT than PE patients, the ANN was trained iteratively as described in the Materials and Methods section. By completion of the iterative algorithm, the final ANN obtained an area under the operative curve (AUC) of 0.89. Of more interest are the performances of the ANN in the testing set. Indeed, our ANN got F1-scores of 0.82 and 0.60 for the DVT and PE classes, respectively, and a global AUC of 0.79 in the testing set.

We then used the LIME algorithm to obtain a local linear approximate of the ANN predictions. In the testing set, the LIME prediction achieved an overall AUC of 0.77 instead of 0.79 for ANN. For each of the 16 patients in the testing set, we compared the individual predictions of their observed VTE event provided by the ANN and LIME methods ( Table 2 ). In general, ANN and LIME predictions were rather consistent even if the ANN predictions seem to be more accurate in predicting DVT while LIME appears slightly more accurate in predicting PE. The average prediction in correctly classifying DVT patients was 0.872 by ANN compared to 0.748 by LIME. Note that one DVT patient (individual 10) was wrongly predicted to be PE by the ANN predictor, but not by the LIME predictor. Conversely, the average prediction in correctly classifying PE patients was 0.498 by ANN compared to 0.578 by LIME. Two PE patients (individuals 11 and 12) presented low predictions of being PE, using both ANN and LIME predictors.

We then assessed the correlation of the LIME predictor with the available biological phenotypes. No strong correlation was observed (Supplementary Table 5 ). However, the LIME predictor showed marginal positive correlation with fibrinogen (ρ = 0.12, p = 5.7 × 10 -3 ) and factor VIII (ρ = 0.16, p = 0.013) plasma levels, and marginal negative correlation with prothrombin time (ρ = −0.10, p = 0.029) and protein S (ρ = −0.10, p = 0.021) plasma levels. To go further into the biological interpretation of the LIME predictor, we sought to identify which proteins contribute the most to the definition of the LIME predictor. Figure 3 display the top 20 most contributing antibodies/proteins. Of note, 5 proteins tended to have substantial more importance than the remaining ones, among which three include proteins that had been selected because their gene expression (COX4I2, VCL, VWF) was found to be specifically enriched in endothelial cells 43 .

To get additional information about the biological mechanisms that could underlie the linear LIME predictor, we conducted a GWAS on this predictor considered as a quantitative linear trait in a sample of 574 individuals of the ANN subsample with GWAS data. While no SNP reached genome-wide significance, we observed a peak of strong suggestive statistical association on chromosome 7 at the PLXNA4 locus ( Supplementary Fig. 1-Supplementary Table 6 ). The sentinel SNP (p = 5.33 × 10 -7 ) was rs1424597 whose minor A allele with frequency of 0.09 was associated with an increase of + 0.169 ± 0.034 in LIME predictor values. We then tested the association of the rs1424597 polymorphisms with PE in the whole MARTHA samples. As shown in Table 3 , the rs1424597-A allele tended to be more frequent in patients with PE than in patients with DVT only (0.11 vs. 0.08). However, looking deeply to the genotypic distribution revealed a pattern of association more compatible with a recessive effect for the rs1424597-A allele. Carriers of the AA genotype were more frequently observed in the PE than in the DVT groups (2% vs. 0.4%), carrying the AA genotype being associated with a significantly higher risk of PE (OR 5.3 [1.7-17.0], p = 0.005). This pattern of recessive association was also observed in the EOVT study composed of 143 PE patients and 196 DVT patient. www.nature.com/scientificreports/ In EOVT, 3% of PE patients were carriers of the AA genotype and none of the DVT patients, the Fisher exact test for the recessive A allele effect being significant (p = 0.013). Looking back to the original GWAS results for the LIME predictor revealed that the association of rs1424597 with the predictor was also compatible with a recessive effect. Mean values for the LIME predictor were 0.33 ± 0.31, 0.48 ± 0.36 and 0.79 ± 0.45, in GG, GA and AA genotypes, respectively. We then interrogated various public resources (See Methods) to investigate if the PLXNA4 rs1424597 could be associated with additional clinical or biological traits as well as regulatory mechanisms. The only robust and strong identified association relates to a meta-analysis of whole blood DNA methylation data performed in more than 27,000 individuals part of the GoDMC consortium (https:// doi. org/ 10. 1101/ 2020. 09. 01. 20180 406) and where rs1424597 was statistically associated (p = 8.7 × 10 -91 ) with methylation levels at the CpG cg06087029 site. The rs1424597-A allele was associated with decreased levels of the cg06087029 site that maps to the ATRIP locus on chromosome 3. Noteworthy, the PLXNA4 polymorphism that associated the most with cg06087029 in GoDMC, rs17219279 (p = 2.7 × 10 -119 ) was in strong linkage disequilibrium with the rs1424597 (r 2 = 0.85, D′ = 0.99) and also demonstrated strong statistical association with our LIME predictor (p = 2.19 × 10 -6 , Supplementary Table 6 ) and PE risk (p = 0.007) in MARTHA. Of note, no evidence for association of rs1424597 with gene expression was reported in the GTEx portal.

Accumulating evidence indicates that vascular dysfunction together with a prothrombotic state underlies severe COVID-19 pathophysiology, with respiratory failure linked to microvascular thrombosis in lung 44, 45 . With the hypothesis that plasma proteins associated with PE risk would potentially be associated with COVID-19 pulmonary complications, we included an antibody targeting PLXNA4 in a plasma proteomic analysis of 339 samples collected at consecutive time points from 112 hospitalized COVID-19 patients. As indicated in Table 4 , plasma PLXNA4 levels tend to slightly decrease with worsened respiratory dysfunction at baseline, patients with Table 2 , our ANN/LIME models failed to correctly predict the true VTE outcome in four individuals from the testing set (individuals 10, 11, 12 and 15). First, it is worthy of note that these 4 individuals were all females. Second, the 3 female PE patients wrongly predicted to be DVT (individuals 11, 12 and 15) were all under oral contraceptives (OC) at the time of the PE event (age 45, 35 and 53, respectively), but not individual 10 incorrectly predicted to be PE. While we cannot rule out the possibility that our ANN/LIME models poorly behave in women under OC, we nevertheless sought to investigate whether discordant predictions could be due to genomic outlier individuals harboring very rare disease causing mutations that could make the global ANN/LIME predictions inaccurate, in line with the idea that the discrepancy between (machine learning derived) predicted and observed phenotypes could be a heritable trait 46 . Among these 4 individuals, only two (Individuals 11 and 15) have been sequenced for their whole genome. Sequence data of these two individuals were then scrutinized for candidate rare variants that could explain the VTE phenotype. Individual 11 is a woman that experienced PE under oral contraceptives (OC) at age 45. Of note, her ten closest neighbors inferred from HPA data were all DVT patients which would likely explain why the derived ANN predicted her a DVT outcome instead of PE. She was not found to harbor any candidate variation in known VTE genes but presented in her genome with 61 very rare coding variants with strong predicted deleteriousness that could be good candidates responsible for the PE event (Supplementary Table 7) .

Individual 15 is a woman that had experienced PE at age 53 also under OC. Nine out of 10 of her closest proteomics based neighbors were DVT patients which may also explain why this PE patient was incorrectly predicted to be DVT. This patient was found to carry a very rare nonsynonymous variation (rs121918154; PROC:NM_000312:exon9:c.C814T:p.R272C) in the VTE-associated PROC gene. This variation has a minor allele frequency of 0.005% in public database (https:// www. ncbi. nlm. nih. gov/ snp/ rs121 918154), is predicted to be deleterious by several bioinformatics tools and have been previously reported in VTE patients with protein C deficiency 47, 48 . This variation is located in the last exon of the gene and is predicted to alter splicing regulatory elements [49] [50] [51] , which could lead to a deletion of a part of the peptidase S1 domain that is responsible for the cleavage activity of the protein. Of note, this patient exhibited moderately low plasma Protein C levels, 63%, slightly lower than the 65% threshold adopted to declare moderate protein C deficiency 52 .

This work is original in at least three main aspects. First, it is the largest plasma proteomic study with respect to pulmonary embolism in VTE patients. Second, it is to our knowledge the first attempt to deploy ANN methodologies on proteomic data with the aim at identifying new molecular thrombotic players. And finally, the integration of proteomic and genomics data identified PLXNA4 as a new candidate gene for PE.

This work started with the implementation of an ANN methodology on antibody based affinity proteomics data in relation to PE risk. This ANN was not developed as a tool to be used in clinic for predicting PE risk as 1/one is not 100% certain about the identity of the identified tagged proteins 53 (further experimental validation would be needed to assess this) and 2/plasma protein levels determined with the antibody suspension bead array are not absolute but relative values depending on the current set of studied antibodies. Rather, we employed this ANN strategy to detect a PE-associated molecular signature that could either reflect nonlinear relationships between investigated proteins or serve as an intermediate surrogate biomarker of an unmeasured variable that could generate new knowledge about the (genetics) mechanisms involved in PE. Our intention is not to claim that the proposed strategy is the panacea but that it can be considered as an appealing strategy compared to others methods. The latter are legion and their exhaustive comparison is out of the scope of the current work. However, preliminary results (see supplementary data) indicate that our ANN strategy performs better on our proteomics data than some popular methodologies such as standard logistic regression and Random Forest. www.nature.com/scientificreports/ By conducting a GWAS on the derived PE linear predictor and capitalizing on two case-control samples totaling 467 patients with PE and 1414 patients with DVT, we observed that VTE patients that were homozygotes carriers of the PLXNA4 rs1424597-A allele were at higher risk of PE.

PLXNA4 codes for Plexin A4, which is part of a receptor complex involved in signal transduction of semaphorin 3 signals linked to cytoskeletal rearrangement, inhibiting integrin adhesion 54, 55 . It has a role in axon guidance in nervous system development, and genetic variants in PLXN4 have been linked to risk of Alzheimer disease 56, 57 . Based on RNA seq data from HPA, FANTOM and GTEx datasets, PLXNA4 is expressed at medium/ high levels in central nervous system, adipose, breast and female reproductive tract tissues, and low levels in a broad range of other tissues (https:// www. prote inatl as. org/ ENSG0 00002 21866-PLXNA4/ tissue), indicating roles outside the nervous system. Despite found in most tissues, based on more recently available data from an integrated analysis of single cell RNA seq data available in public repositories (https:// www. prote inatl as. org/ human prote ome/ cellt ype), the cell types in which PLXNA4 is expressed in is tissue dependent. For example, in liver it is expressed in endothelial cells together with a low expression in ITO cells but no expression in other cell types found, while in lung, it is found to be expressed in fibroblasts, T cells and granulocytes, but not identified in endothelial cells. In RNA seq data from sorted blood cell populations, PLXNA4 show expression predominantly in plasmacytoid dendritic cells, together with NK cells and low level of expression in some T cell populations. Together, this indicates an organ and cell type dependent regulation of PLXNA4 expression, which could suggest different role in different tissues. Research based on animal studies suggest a role in immunity and immune function, where it has been shown to be a negative regulator of T cell activation 58 . One of the PLXNA4's ligand, SEMA3, has also been described with a role in endothelial cell function in an autocrine loop, promoting processes involved in vascular remodeling 59 , and also in negatively regulating platelet aggregation 60 . While PLXNA4 thus has been described with a role in processes/pathways of relevance for thrombosis, little is known about PLXNA4 in pulmonary embolism.

Symptoms of COVID-19, the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), include fever, fatigue, dry cough and dyspnea. While most individuals experience mild to moderate disease, a proportion progress of infected individuals progress to severe or critical disease with pneumonia, acute respiratory distress syndrome 45 , endotheliopathy leading to microvascular thrombotic complications 61 contributing to the high incidence of pulmonary embolism observed in COVID-19 patients 62 . By plasma proteomics analysis of 339 samples from 112 hospitalized patients in the COMMUNITY STUDY, we found that plasma levels of PLXNA4 were associated with level of respiratory support needed in critically ill COVID-19 patients.

Nevertheless, we did not identify strong elements supporting a functional role of the intronic rs1424597 polymorphisms or of any other polymorphisms in strong linkage disequilibrium with it. The rs1424597 has recently been observed to associate in trans with whole blood DNA methylation levels at the ATRIP locus. However, based on scRNAseq data, the cell type expression profile of ATRIP in different organs and tissues does not match that of PLXNA4 to any notable extent, making difficult any straightforward interpretation of the trans association. Besides, in the FinnGen study (http:// r3. finng en. fi/), it has been reported to marginally (p = 4.5 × 10 -3 ) associate with pleural conditions that are inflammatory disorders of the lung. Consistent with this observation, we observed a positive correlation between the rs1424597-associated PE predictor and fibrinogen, a well-known inflammatory marker. Additional PLXNA4 polymorphisms have also been reported to demonstrate strong statistical evidence for association with various lung function markers 63, 64 . Altogether, these observations strongly support for a role of PLXNA4 in lung function and its precise role in the etiology of pulmonary embolism deserve further investigation. Which polymorphisms could be truly responsible for the observed association with PE risk also merits further works as the rs1424597 is likely tagging for functional variant(s)/haplotypes yet to be characterized.

In addition to searching for common polymorphisms that could associate with our ANN based predictor and with PE risk, we also looked for rare variants that could explain the discrepancy between predicted and observed VTE outcome in our testing set. Two out of four patients with discordant predictions in the testing set have been sequenced for their whole genome. Both were female patients that experienced PE under OC. In one of them, we were able to identify a rare VTE causing mutation in PROC. It is not our intention to conclude to any general rule about the relevance of searching of rare variants responsible for any discordancy between ANN predictions and observed outcomes. Especially as we observed that the three PE patients wrongly predicted to be DVT were women who developed PE under OC. These observations could suggest that our plasma proteomics ANN derived predictions may not be valid in such subgroups of VTE patients and highlight the challenge to identify general prediction models for complex diseases. Several additional limitations must be addressed.

First, the under sampling strategy we deployed to select patients that will be used in the ANN approach have led to a selection of DVT patients that may no longer be representatives of the whole population of DVT patients as we have discarded DVT patients that are very close, with respect to their biological and proteomic data, to PE patients. As a consequence, the PLXNA4 locus we identified is likely a susceptibility locus for PE only in a subgroup of VT patients with specific characteristics that need to be identified. Second, no plasma antibody targeting PLXNA4 was available when the screening phase of this work was initiated preventing us from validating further its association with PE. Third, no proteomic data was available in the EOVT study to formally replicate the association of our ANN and LIME predictors with PE risk. Fourth, our GWAS analysis on the ANN derived predictor was performed only in 574 samples which has likely hampered our power to identify genome-wide significant SNPs. We may have then missed additional polymorphisms that could be truly associated with the predictor and could have then helped us to better disentangle its underlying molecular biology. Finally, the moderate sample size of the EOVT study has also likely hampered our power for statistically replicating the association of the lead PLXNA4 polymorphism with PE. In addition, no information was available in the EOVT study to distinguish isolated PE From DVT + PE which prevented us from further testing whether the association of PLXNA4 with PE risk was mainly restricted to isolated PE as suggested from the MARTHA results. www.nature.com/scientificreports/ In conclusion, by implementing an original artificial neural network methodology integrating plasma proteomics and genetic data, we identified PLXNA4 as a new candidate susceptibility gene for PE in VTE patients whose precise role in PE etiology deserves further investigations. www.nature.com/scientificreports/ Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.

The epidemiology of venous thromboembolism

ESC guidelines on the diagnosis and management of acute pulmonary embolism

Pulmonary embolism or thrombosis in ARDS COVID-19 patients: A French monocenter retrospective study

Protein expression profiling suggests relevance of non-canonical pathways in isolated pulmonary embolism

Broadening the factor V Leiden paradox: Pulmonary embolism and deep-vein thrombosis as 2 sides of the spectrum

A platelet function modulator of thrombin activation is causally linked to cardiovascular disease and affects PAR4 receptor signaling

Association of recurrent venous thromboembolism and circulating microRNAs

Bayesian network analysis of plasma microRNA sequencing data in patients with venous thrombosis

PDGFB, a new candidate plasma biomarker for venous thromboembolism: Results from the VEREMA affinity proteomics study

Discovery of novel plasma biomarkers for future incident venous thromboembolism by untargeted synchronous precursor selection mass spectrometry proteomics

Plasma biomarkers and identification of resilient metabolic disruptions in patients with venous thromboembolism using a metabolic systems approach

Metabolomic analysis of 92 pulmonary embolism patients from a nested case-control study identifies metabolites associated with adverse clinical outcomes

Identification of reduced circulating haptoglobin concentration as a biomarker of the severity of pulmonary embolism: A nontargeted proteomic study

Proteomics. Tissue-based map of the human proteome

Genome wide association study for plasma levels of natural anticoagulant inhibitors and protein C anticoagulant pathway: The MARTHA project

Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism

Asymptotic properties of nearest neighbor rules using edited data

Why should I trust you? Explaining the predictions of any classifier

Genomic atlas of the human plasma proteome

Connecting genetic risk to disease end points through the human blood plasma proteome

Genetics of venous thrombosis: Insights from a new genome wide association study

Highly multiplexed antibody suspension bead arrays for plasma protein profiling

Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: Results from a GWAS approach

Adaptive synthetic sampling approach for imbalanced learning

Digital selection and analogue amplification coexist in a cortex-inspired silicon circuit

Probabilistic interpretation of feedforward classification network outputs, with relationships to statistical pattern recognition

The 'wake-sleep' algorithm for unsupervised neural networks

The method of steepest descent for non-linear minimization problems

Integrating genome-wide genetic variations and monocyte expression data reveals trans-regulated gene modules in humans

Identification of CAD candidate genes in GWAS loci and their expression in vascular cells

Preservation analysis of macrophage gene coexpression between human and mouse identifies PARK2 as a genetically controlled master regulator of oxidative phosphorylation in humans

Whole blood levels of S1PR4 mRNA associated with cerebral vasospasm after aneurysmal subarachnoid hemorrhage

Pulmonary embolism in patients with COVID-19: Awareness of an increased prevalence

Prothrombotic changes in patients with COVID-19 are associated with disease severity and mortality

Fast and accurate short read alignment with Burrows-Wheeler transform

ANNOVAR: Functional annotation of genetic variants from high-throughput sequencing data

Whole-exome sequencing identifies rare variants in STAB2 associated with venous thromboembolic disease

Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism

What is currently known about the genetics of venous thromboembolism at the dawn of next generation sequencing technologies

A general framework for estimating the relative pathogenicity of human genetic variants

Visualizing data using t-SNE

UMAP: Uniform manifold approximation and projection for dimension reduction

Analysis of body-wide unfractionated tissue data to identify a core human endothelial transcriptome

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases

Time course of a second outbreak of COVID-19 in Beijing, China

Brain age prediction using deep learning uncovers associated sequence variants

Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect

The spectrum of genetic defects in a panel of 40 Dutch families with symptomatic protein C deficiency type I: Heterogeneity and founder effects

Genomic HEXploring allows landscaping of novel potential splicing regulatory elements

Quantitative evaluation of all hexamers as exonic splicing elements

Large-scale comparative evaluation of user-friendly tools for predicting variant-induced alterations of splicing regulatory elements

Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives

Systematic assessment of antibody selectivity in plasma based on a resource of enrichment profiles

Semaphorins and their receptors: From axonal guidance to atherosclerosis

Semaphorins in health and disease

Common variants in PLXNA4 and correlation to CSF-related phenotypes in Alzheimer's disease

PLXNA4 is associated with Alzheimer disease and modulates tau phosphorylation

Plexin-A4 negatively regulates T lymphocyte responses

Semaphoring vascular morphogenesis

Negative regulation of platelet function by a secreted cell repulsive protein, semaphorin 3A

Endothelial cell infection and endotheliitis in COVID-19

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

A genome-wide analysis of the response to inhaled β2-agonists in chronic obstructive pulmonary disease. Pharmacogenom

Genome-wide association study of lung function decline in adults with and without asthma

Proteomics data used in this work are available at https:// zenodo. org/ record/ 42807 76#. YCEVV eoo-vc. 

The authors declare no competing interests.

The online version contains supplementary material available at https:// doi. org/ 10. 1038/ s41598-021-93390-7.Correspondence and requests for materials should be addressed to M.R. or D.-A.T.Reprints and permissions information is available at www.nature.com/reprints.